Tag: Cancer
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall

AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall

Study by Lunit and Korean academic hospital Published in Lancet Digital Health SEOUL, South Korea, Feb. 10, 2020 /PRNewswire/ -- A new study, published in Lancet Digital ...

Lees verder
Encore Medical Education Will Publish the Official Best of SABCS® News From the 2019 San Antonio Breast Cancer Symposium (SABCS®) Starting Decemb

Encore Medical Education Will Publish the Official Best of SABCS® News From the 2019 San Antonio Breast Cancer Symposium (SABCS®) Starting Decemb

SAN ANTONIO, Texas, Nov. 1, 2019 /PRNewswire/ -- Encore Medical Education (www.encoremeded.com ) will publish the Official SABCS(®) News highlighting the key findings presented ...

Lees verder
Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

DARMSTADT, Germany, May 15, 2019 /PRNewswire/ -- Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; ...

Lees verder
GammaPod Stereotactic Radiotherapy System for Breast Cancer Receives CE Mark

GammaPod Stereotactic Radiotherapy System for Breast Cancer Receives CE Mark

Xcision to Highlight Short, Noninvasive and Patient Friendly Treatment Option at ESTRO 38 in Milan, Italy from April 26-30 COLUMBIA, Maryland, April 25, 2019 /PRNewswire/ -- ...

Lees verder
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media   Merck and Pfizer Inc. today announced that data from a ...

Lees verder
Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

DARMSTADT, Germany, December 20, 2018 /PRNewswire/ -- The information contained is not intended for distribution in the USA, Canada or the UK    - European Medicine ...

Lees verder
Encore Medical Education Will Publish the Best of SABCS® News From 2018 San Antonio Breast Cancer Symposium (SABCS®)

Encore Medical Education Will Publish the Best of SABCS® News From 2018 San Antonio Breast Cancer Symposium (SABCS®)

SAN ANTONIO, December 1, 2018 /PRNewswire/ -- Encore Medical Education will publish the Best of SABCS(R) News highlighting the key findings presented at the 41st San Antonio ...

Lees verder
Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media  Merck and Pfizer Inc. today announced that the Phase III ...

Lees verder
RevitaLash® Cosmetics Maintains Tireless Commitment to Breast Cancer Awareness

RevitaLash® Cosmetics Maintains Tireless Commitment to Breast Cancer Awareness

Annual Brand Pink Campaign Supporting Breast Cancer Kicks Off with Global Giving VENTURA, California, Sept. 14, 2018 /PRNewswire/ -- A proud supporter of year-round breast ...

Lees verder
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published

TOKYO, June 29, 2018 /PRNewswire/ -- Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 ...

Lees verder
BizPress.nl